Related Experiment Video
Updated: May 22, 2025
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice
Hashini I Wanniarachchi1, Regan Schuetze1, Yuling Deng2
1Department of Radiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9058, USA.
Abstract:
There has been much progress in treating kidney cancer, with several new drugs being approved over the last few years [...].
Insights
Recent advancements offer new hope for kidney cancer patients. Several novel therapies have been approved, improving treatment outcomes for this complex disease.
Area of Science:
- Oncology
- Nephrology
Background:
- Kidney cancer treatment has seen significant advancements.
- Several new therapeutic agents have gained approval recently.
Purpose of the Study:
- To review the progress in kidney cancer treatment.
- To highlight newly approved drugs and their impact.
Main Methods:
- Literature review of recent clinical trials and approvals.
- Analysis of treatment efficacy and safety data.
Main Results:
- Multiple new drugs have been approved for kidney cancer.
- These therapies represent significant progress in patient care.
Conclusions:
- The landscape of kidney cancer treatment is rapidly evolving.
- New drug approvals offer improved options for patients.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020